Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation.

[1]  Samuel T. Jones,et al.  Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. , 2018 .

[2]  E. Allémann,et al.  Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation. , 2018, International journal of pharmaceutics.

[3]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[4]  Vincenzo Amendola,et al.  Surface plasmon resonance in gold nanoparticles: a review , 2017, Journal of physics. Condensed matter : an Institute of Physics journal.

[5]  Barbara Rothen-Rutishauser,et al.  A rapid screening method to evaluate the impact of nanoparticles on macrophages. , 2017, Nanoscale.

[6]  Prabhani U. Atukorale,et al.  High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry , 2017, Nature Communications.

[7]  F. Stellacci,et al.  A centrifugation-based physicochemical characterization method for the interaction between proteins and nanoparticles , 2016, Nature Communications.

[8]  C. Hotz,et al.  Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses , 2016, Oncoimmunology.

[9]  Chiara Secondini,et al.  TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function , 2016, Oncoimmunology.

[10]  T. Kaisho,et al.  Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. , 2016, Cancer cell.

[11]  Ronnie H. Fang,et al.  Nanoparticle-Based Modulation of the Immune System. , 2016, Annual review of chemical and biomolecular engineering.

[12]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[13]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[14]  K. Ulbrich,et al.  Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies. , 2016, Chemical reviews.

[15]  Frederic Bartumeus,et al.  T cell migration, search strategies and mechanisms , 2016, Nature Reviews Immunology.

[16]  Sandor Balog,et al.  Nanoparticle colloidal stability in cell culture media and impact on cellular interactions. , 2015, Chemical Society reviews.

[17]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[18]  P. Chakravarty,et al.  GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. , 2015, Immunity.

[19]  Yang Yang,et al.  Nanoparticle-based immunotherapy for cancer. , 2015, ACS nano.

[20]  Rogério Gaspar,et al.  Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking , 2014, Front. Chem..

[21]  S. Bertholet,et al.  Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants , 2014, Proceedings of the National Academy of Sciences.

[22]  Min Beom Heo,et al.  Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. , 2014, Biomaterials.

[23]  Darrell J Irvine,et al.  Engineering synthetic vaccines using cues from natural immunity. , 2013, Nature materials.

[24]  F. Stellacci,et al.  Erythrocyte incubation as a method for free-dye presence determination in fluorescently labeled nanoparticles. , 2013, Molecular pharmaceutics.

[25]  Karolina Palucka,et al.  Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.

[26]  C. Hotz,et al.  Systemic cancer immunotherapy with Toll-like receptor 7 agonists , 2012, Oncoimmunology.

[27]  C. Hotz,et al.  Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. , 2011, Cancer research.

[28]  Jian Zhang,et al.  Physical and chemical stability of drug nanoparticles. , 2011, Advanced drug delivery reviews.

[29]  D. Cantrell,et al.  Metabolism, migration and memory in cytotoxic T cells , 2011, Nature Reviews Immunology.

[30]  S. Fuchs,et al.  Delivery of Immunostimulatory RNA Oligonucleotides by Gelatin Nanoparticles Triggers an Efficient Antitumoral Response , 2010, Journal of immunotherapy.

[31]  W. Zimmermann,et al.  Efficient Eradication of Subcutaneous but Not of Autochthonous Gastric Tumors by Adoptive T Cell Transfer in an SV40 T Antigen Mouse Model , 2010, The Journal of Immunology.

[32]  Richard A Flavell,et al.  Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. , 2009, Vaccine.

[33]  V. Rotello,et al.  Entrapment of hydrophobic drugs in nanoparticle monolayers with efficient release into cancer cells. , 2009, Journal of the American Chemical Society.

[34]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[35]  J. McHutchison,et al.  Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. , 2007, Journal of hepatology.

[36]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[37]  Melody A. Swartz,et al.  Dendritic-cell trafficking to lymph nodes through lymphatic vessels , 2005, Nature Reviews Immunology.

[38]  B. Wüthrich,et al.  Direct intralymphatic injection of peptide vaccines enhances immunogenicity , 2005, European journal of immunology.

[39]  T. Kündig,et al.  Immunity in response to particulate antigen-delivery systems. , 2005, Advanced drug delivery reviews.

[40]  W. Sterry,et al.  The use of Toll‐like receptor‐7 agonist in the treatment of basal cell carcinoma: an overview , 2003, The British journal of dermatology.

[41]  R. Foà,et al.  The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. , 2003, Cancer research.

[42]  R. Noelle,et al.  Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. , 2002, Cellular immunology.

[43]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[44]  R. Zinkernagel,et al.  Intralymphatic immunization enhances DNA vaccination , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[46]  R. Miller,et al.  Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. , 1999, Cellular immunology.

[47]  D. Cooper,et al.  Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. , 1998, The Journal of infectious diseases.

[48]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[49]  N L Tilney,et al.  Patterns of lymphatic drainage in the adult laboratory rat. , 1971, Journal of anatomy.